October 27, 2023
12P Immuno-suppressive role of tumour-derived GDF-15 on myeloid cells
Schuberth-Wagner, C., Giese, I., Kist, M., Vashist, N., Genßler, S., Haack, B.,...
Read More
October 26, 2023
CatalYm commences Dosing in a Phase 2 Study with Visugromab in Combination with Neoadjuvant Immunotherapy in Treatment-naive Muscle Invasive Bladder Cancer Patients
CatalYm commences Dosing in a Phase 2 Study with Visugromab in Combination...
Read More
October 16, 2023
CatalYm Presents Data at ESMO 2023 Expanding GDF-15’s Role in Checkpoint Therapy Resistance by Inhibition of Myeloid Immune Cell Activation
CatalYm Presents Data at ESMO 2023 Expanding GDF-15’s Role in Checkpoint Therapy...
Read More
October 12, 2023
Cancer immunotherapy: GDF-15’s role in Anti-PD-1 resistance
Interview with Christine Schuberth-Wagner, Chief Scientific Officer at CatalYm / Drug Target...
Read More
October 12, 2023
Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment
Markus Haake, Beatrice Haack, Tina Schäfer, Patrick N. Harter, Greta Mattavelli, Patrick...
Read More
July 20, 2023
CatalYm Publishes Data in Nature Communications Describing GDF-15 as a Central Factor of anti-PD-1 Resistance
CatalYm Publishes Data in Nature Communications Describing GDF-15 as a Central Factor...
Read More
June 5, 2023
CatalYm Announces Initial Data from Ongoing Phase 2a Trial Evaluating GDF-15-targeting Antibody Visugromab in Combination with Nivolumab at ASCO 2023
CatalYm Announces Initial Data from Ongoing Phase 2a Trial Evaluating GDF-15-targeting Antibody...
Read More
May 25, 2023
CatalYm to Present Early Phase 2a Data on GDF-15 Neutralizing Antibody Visugromab at the 2023 ASCO Annual Meeting
CatalYm to Present Early Phase 2a Data on GDF-15 Neutralizing Antibody Visugromab...
Read More